Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis

被引：2
|
作者：
Chin, Peter [1 ]
Chan, Andrew C. [2 ]
机构：
[1] Genentech Inc, Med Affairs, One DNA Way, San Francisco, CA 94080 USA
[2] Genentech Inc, Res, One DNA Way, San Francisco, CA 94080 USA
来源：
BIOCHEMISTRY | 2018年 / 57卷 / 05期
关键词：
RITUXIMAB; PLACEBO;
D O I：
10.1021/acs.biochem.7b00796
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
[No abstract available]
引用
收藏
页码：474 / 476
页数：3
相关论文
共 50 条
  • [21] Ocrelizumab in multiple sclerosis: risks and benefits Reply
    Kappos, Ludwig
    Leppert, David
    Timmermann, Jeroen
    Glanzman, Robert
    Hauser, Stephen
    LANCET, 2012, 379 (9822): : 1197 - 1197
  • [22] Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1714):
  • [23] Pharmacogenomic prediction of ocrelizumab outcomes in multiple sclerosis
    Zhong, Michael
    Campagna, Maria Pia
    Sampangi, Sandeep
    Kermode, Allan
    Pedrini, Marzena
    Lechner-Scott, Jeannette
    Maltby, Vicki
    van der Walt, Anneke
    Butzkueven, Helmut
    Jokubaitis, Vilija
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 973 - 974
  • [24] Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis
    Mildiner, Sorcha
    Malnick, Stephen
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17): : 1692 - 1693
  • [25] Ocrelizumab: its efficacy and safety in multiple sclerosis
    Juanatey, Ana
    Blanco-Garcia, Laura
    Tellez, Nieves
    REVISTA DE NEUROLOGIA, 2018, 66 (12) : 423 - 433
  • [26] UPDATED SAFETY ANALYSIS OF OCRELIZUMAB IN MULTIPLE SCLEROSIS
    Young, Carolyn
    Hauser, Stephen
    Kappos, Ludwig
    Montalban, Xavier
    Hughes, Richard
    Koendgen, Harold
    McNamara, John
    Pradhan, Ashish
    Wormser, David
    Wolinsky, Jerry
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (12): : E56 - E56
  • [27] Beyond ocrelizumab in primary progressive multiple sclerosis
    Thomas Williams
    Jeremy Chataway
    Nature Reviews Neurology, 2022, 18 : 641 - 642
  • [28] Extended interval dosing with ocrelizumab in multiple sclerosis
    Novak, Frederik
    Bajwa, Hamza Mahmood
    Ostergaard, Kamilla
    Berg, Jonas Munksgaard
    Madsen, Jonna Skov
    Olsen, Dorte Aalund
    Urbonaviciute, Inga
    Illes, Zsolt
    Stilund, Morten Leif
    Christensen, Jeppe Romme
    Bramow, Stephan
    Sellebjerg, Finn
    Sejbaek, Tobias
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (07) : 847 - 856
  • [29] Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
    Maria Cellerino
    Giacomo Boffa
    Caterina Lapucci
    Francesco Tazza
    Elvira Sbragia
    Elisabetta Mancuso
    Nicolò Bruschi
    Simona Minguzzi
    Federico Ivaldi
    Ilaria Poirè
    Alice Laroni
    Gianluigi Mancardi
    Elisabetta Capello
    Antonio Uccelli
    Giovanni Novi
    Matilde Inglese
    Neurotherapeutics, 2021, 18 : 2579 - 2588
  • [30] Beyond ocrelizumab in primary progressive multiple sclerosis
    Williams, Thomas
    Chataway, Jeremy
    NATURE REVIEWS NEUROLOGY, 2022, 18 (11) : 641 - 642
12345